Role of montelukast in multitrigger wheezers, finds Study
Wheeze is seen in 40% of preschool children, 1/3rd of these may develop recurrent wheeze. Montelukast is an oral, once a day, easy to give therapy. Present study was done to evaluate role of daily montelukast and various factors affecting the outcome after therapy in multitrigger wheeze (MTW).

A forward-looking study was carried out in DMCH, Ludhiana in more than 18 months. Montelukast was initiated for children aged 6 months to 5 years, diagnosed MTW patients. The pediatrician in charge of the chest clinic made a diagnosis based on recurring wheat symptoms produced by different allergens/precipitants. 1 and 3 months of follow-up were followed by children. They have been designated controlled, partly controlled or uncontrolled by the global asthma recommendations project. The results connected to numerous aspects have been compared using data.

--Total 139 out of 150 children came for regular follow-up. At the end of 3 months, 94 were controlled, 8 partially controlled, and 37 children remained uncontrolled on montelukast.

--Factors associated with poor control were onset of symptoms at younger age (less than 6 months of age), family history of allergies, prior multiple visits or hospitalizations due to MTW, use of MDI in the past.

--No significant side effects were reported by parents.

In the end, two thirds of children symptomatically improved following the beginning of montelukast. In subgroups of patients there were few factors which led to less control.